Sarcoma

Soft tissue sarcoma
#Clinical trial #RNA modifying enzymes #Sarcoma

Enzyme inhibitor shows early evidence of treating sarcoma 

An RNA-modifying enzyme inhibitor has shown positive results in treating sarcoma patients during a Phase I trial.  STC-15, developed by STORM Therapeutics, demonstrated a disease control rate of 54% at 12 weeks and a median progression-free survival of six months. The trial enrolled 42 patients with advanced… Read More

#Cancer Research #News

Soft tissue sarcoma
#Investment #Sarcoma #Storm Therapeutics

STORM secures $56m financing for sarcoma treatment 

Biotechnology company STORM Therapeutics has announced it has secured $56 million in a Series C financing to support its sarcoma treatment.  The proceeds will support the advancement of STC-15, a first‑in‑class, oral small-molecule inhibitor of METTL3. This extends to funding the company’s Phase II monotherapy study… Read More

#Business & Investment #News

Soft tissue sarcoma
#Oncology #Phase II trial #Sarcoma #Vyome Therapeutics

Topical gel could be a breakthrough in cancer wounds

Vyome Therapeutics has shared interim results from its Phase II proof of concept study of VT-1953 topical gel in people with malignant fungating wounds (MFW).  VT-1953, which exerts an immuno-anti-inflammatory effect by targeting TLR-MD2 and DNA gyrase, met its primary endpoint in this interim analysis, with patients… Read More

#Cancer Research #News